AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of ...

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products. Pharmaceutical giant AstraZeneca announced its fourth ...

AstraZeneca is facing some headwinds related to its operations in China. Still, the company's financial results and pipeline look strong. The stock could deliver solid returns for those who invest ...

AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. The drugmaker successfully defended itself against claims senior staff ignored requests ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. Get access to the leaderboards pointing to tomorrow’s biggest ...

AstraZeneca topped Wall Street revenue and earnings estimates. The big pharma company also raised its full-year revenue and earnings guidance. However, many investors appear to have been hoping ...

AstraZeneca has appointed WPP as one of its primary oncology network partners. Under WPP’s new remit as a global creative partner, the agency will support U.S. and global advertising for AstraZeneca’s ...

AstraZeneca’s booming oncology business has won over cancer patient groups. Having languished down the leaderboard in the past, the drugmaker vaulted (PDF) over many rivals in PatientView’s ...

AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand. The vaccine — called Vaxzevria and ...

By Rebecca Robbins AstraZeneca has started to pull its Covid-19 vaccine from global markets because of low demand, the pharmaceutical giant said. The decision closes the chapter on a shot that was ...